Abstract The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis.
In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive …

Patients with COVID-19 show a high prevalence of liver injury. The pattern of this liver
damage is still not fully understood. Different etiopathogenetic factors may concur; from a …

To better understand the mechanisms at the basis of neutrophil functions during SARS‐CoV‐
2, we studied patients with severe COVID‐19 pneumonia. They had high blood proportion of …

In recent years, humanity has been confronted with a global pandemic due to coronavirus
disease 2019 (COVID-19), which has caused an unprecedented health and economic crisis …

In the last few years, the world has had to face the SARS-CoV-2 infection and its multiple
effects. Even though COVID-19 was first considered to be a respiratory disease, it has an …

Background Data on the safety and efficacy profile of tocilizumab in patients with severe
COVID-19 needs to be enriched. Methods In this open label, prospective study, we …

Severe manifestations of COVID-19 consist of acute respiratory distress syndrome due to an
initially local reaction leading to a systemic inflammatory response that results in hypoxia …

Tocilizumab (TOC) is presumed to be an effective and safe treatment for severe COVID-19,
but its usefulness has not been yet investigated for different SARS-CoV-2 variants. This …

The consequences of coronavirus disease 2019 (COVID-19) are particularly severe in older
adults with a disproportionate number of severe and fatal outcomes. Therefore, this …

Objectives Evidence supports tocilizumab (TCZ) benefit and safety in adult patients with
severe COVID-19. However, its effectiveness in critically ill older adult patients remains …